Citi raised the firm’s price target on Cooper Companies to $116 from $108 and keeps a Buy rating on the shares as part of a Q1 earnings preview for the medical technology group. Expectations are “medium-to-high” for solid deliveries, encouraged by new products and pent-up demand, the analyst tells investors in a research note. The firm says that while the group has traded in-line with the market year-to-date, “it doesn’t really tell the current MedTech story.” Citi believes the Q1 reports should set-up the remainder of the year, hurdling tough year-over-year compares, as new products remain in focus. Its top picks remain Boston Scientific (BSX), Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COO:
- Cooper Companies upgraded to Buy from Neutral at Redburn Atlantic
- Tesla downgraded, Southwest upgraded: Wall Street’s top analyst calls
- Cooper Companies upgraded to Overweight from Neutral at JPMorgan
- Early notable gainers among liquid option names on March 1st
- Cooper Companies price target raised to $114 from $105 at BofA